Tyrosine kinase inhibition increases functional parkin‐ Beclin‐1 interaction and enhances amyloid clearance and cognitive performance
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs) are effective therapies for leukaemia. Alzheimer is a neurodegenerative disease characterized by accumulation of β-amyloid (plaques) and hyper-phosphorylated Tau (tangles). Here we show that AD animals have high levels of insoluble parkin and decreased parkin-Beclin-1 interaction, while peripheral administration of TKIs, including Nilotinib and Bosutinib, increases soluble parkin leading to amyloid clearance and cognitive improvement. Blocking Beclin-1 expression with shRNA or parkin deletion prevents tyrosine kinase (TK) inhibition-induced amyloid clearance, suggesting that functional parkin-Beclin-1 interaction mediates amyloid degradation. Isolation of autophagic vacuoles (AVs) in AD mouse brain shows accumulation of parkin and amyloid, consistent with previous results in AD brains, while Bosutinib and Nilotinib increase parkin-Beclin-1 interaction and result in protein deposition in the lysosome. These data suggest that decreased parkin solubility impedes parkin-Beclin-1 interaction and amyloid clearance. We identified two FDA-approved anti-cancer drugs as potential treatment for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“Mutations in the gene coding for the E3 ‐ ubiquitin ligase parkin ( Park2 ) are associated with inherited PD (Kitada et al, 1998).”
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · cited 1×
“Parkin mediates autophagic degradation of defective mitochondria (mitophagy) (Geisler et al, 2010; Narendra et al, 2008; Park et al, 2009; Vives ‐ Bauza et al, 2010), and clears autophagic vacuoles (AVs) in AD and PD models (Khandelwal et al, 2011; Lonskaya et al, 2012a; Lonskaya et al, 2012c),…”
Regulation mechanisms and signaling pathways of autophagy
He, C., & Klionsky, D. J. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102808-114910 · Cited by 3,609 · cited 2×
“Autophagosome accumulation could be due to lack of maturation, leading to inef fi cient fusion with lysosomes and decreased autophagic clearance (He & Klionsky, 2009; Iwata et al, 2005; Kovács et al, 1982).”
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., & Springer, W. (2010) · Nature Cell Biology · doi:10.1038/ncb2012 · Cited by 2,835 · cited 1×
“Parkin mediates autophagic degradation of defective mitochondria (mitophagy) (Geisler et al, 2010; Narendra et al, 2008; Park et al, 2009; Vives ‐ Bauza et al, 2010), and clears autophagic vacuoles (AVs) in AD and PD models (Khandelwal et al, 2011; Lonskaya et al, 2012a; Lonskaya et al, 2012c),…”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419 · cited 1×
“We con fi rmed the interaction between parkin and Beclin ‐ 1 using in situ proximity ligation assay (PLA), which allows direct observation of individual endogenous protein complexes (Soderberg et al, 2006).”
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 1×
“Src tyrosine kinase (TK) is also recognized in AD pathology via interaction with Tau (Ittner et al, 2010; Lee, 2005; Reynolds et al, 2008).”
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy
Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L. A., Kim, J., May, J., Tocilescu, M. A., Liu, W., Ko, H. S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911187107 · Cited by 1,616
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 1×
“…to yield C ‐ terminal APP fragments (CTFs), and amyloid peptides A b 1 – 40 and A b 1 – 42 (Cook et al, 1997; Green fi eld et al, 1999; Skovronsky et al, 1998; Xu et al, 1997) that give rise to extracellular plaques (D ’ Andrea et al, 2001; Gouras et al, 2000; Li et al, 2007; Oddo et al, 2003).”
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 1×
“…to yield C ‐ terminal APP fragments (CTFs), and amyloid peptides A b 1 – 40 and A b 1 – 42 (Cook et al, 1997; Green fi eld et al, 1999; Skovronsky et al, 1998; Xu et al, 1997) that give rise to extracellular plaques (D ’ Andrea et al, 2001; Gouras et al, 2000; Li et al, 2007; Oddo et al, 2003).”
HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.
Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508786200 · Cited by 719 · cited 2×
“Autophagosome accumulation could be due to lack of maturation, leading to inef fi cient fusion with lysosomes and decreased autophagic clearance (He & Klionsky, 2009; Iwata et al, 2005; Kovács et al, 1982).”
Cited by
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
Autophagy in Alzheimer’s disease pathogenesis: Therapeutic potential and future perspectives
Zhang, Z., Yang, X., Song, Y.-Q., & Tu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101464 · Cited by 369
Gelmetti, V., De Rosa, P., Torosantucci, L., Marini, E. S., Romagnoli, A., Di Rienzo, M., Arena, G., Vignone, D., Fimia, G. M., & Valente, E. M. (2017) · Autophagy · doi:10.1080/15548627.2016.1277309 · Cited by 350
Development of autophagy inducers in clinical medicine
Levine, B., Packer, M., & Codogno, P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73938 · Cited by 347
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Self-citation
Metadata
- Authors
- Lonskaya, I., Hebron, M. L., Desforges, N. M., Franjie, A., & Moussa, C. E. ‐.
- Venue
- EMBO Molecular Medicine
- Published
- 2013-07-04
- Volume
- 5
- Issue
- 8
- Pages
- 1247-1262
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W1883048423
- Cited by
- 140
- References
- 20
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tyrosine kinase inhibition increases functional parkin‐ Beclin‐1 interaction and enhances amyloid clearance and cognitive performance. https://app.cochat.ai/papers/10.1002/emmm.201302771
- The paper
- Lonskaya, I., Hebron, M. L., Desforges, N. M., Franjie, A., & Moussa, C. E. ‐. (2013). Tyrosine kinase inhibition increases functional parkin‐ Beclin‐1 interaction and enhances amyloid clearance and cognitive performance. EMBO Molecular Medicine. https://doi.org/10.1002/emmm.201302771
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.